Gland Pharma Ltd. (GLAND) AI Stock Analysis

• Market Cap: ₹332.95B
• Dividend Yield: 0.89%
• Average Volume (3M): 6.59K
• Price to Earnings (P/E): 43.2
• Beta (1Y): 0.49
• Revenue Growth: -2.34%
• EPS Growth: 6.64%
• Country: IN
• Employees: 4,217
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 13.08
• Shares Outstanding: 164,756,420
• 10 Day Avg. Volume: 5,330
• 30 Day Avg. Volume: 6,589
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,883.14
• Price Target Upside: -6.81% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 7

• Rating: 69 Neutral
• Price Target: ₹2,102.00 ▲(4.02% Upside)

Gland Pharma Ltd. shows strong financial performance with consistent growth and a robust balance sheet, which is the most significant factor in its overall score. Technical analysis indicates a stable trend but with bearish momentum, while valuation metrics suggest the stock is relatively expensive. The absence of earnings call data and corporate events limits further insights.

Positive Factors

Strong Balance Sheet

A strong balance sheet with low financial leverage provides Gland Pharma with the stability to weather economic fluctuations and invest in growth opportunities.

Diverse Revenue Streams

Diverse revenue streams from global markets and partnerships reduce dependency on any single market, enhancing resilience and growth potential.

Efficient Cash Flow Management

Strong cash flow management ensures Gland Pharma can sustain operations, invest in R&D, and manage liabilities effectively, supporting long-term growth.

Negative Factors

Decline in Revenue Growth

A recent decline in revenue growth could indicate challenges in market expansion or increased competition, potentially impacting future profitability.

Decreasing Free Cash Flow Growth

Decreasing free cash flow growth may limit Gland Pharma's ability to fund new projects or return capital to shareholders, affecting long-term strategic flexibility.

Recent Decline in Net Income

A decline in net income suggests potential issues in cost management or pricing power, which could affect profitability if not addressed.

Gland Pharma Ltd. Business Overview & Revenue Model

Company Description

Gland Pharma Ltd. (GLAND) is an Indian pharmaceutical company that specializes in the production of injectable products. Established in 1978, the company is known for manufacturing a wide range of complex injectables, including biosimilars, peptides, and long-acting injectables. It operates across various therapeutic areas such as anti-infectives, oncology, and cardiovascular, providing products that cater to both regulated and emerging markets.

How the Company Makes Money

Gland Pharma Ltd. generates revenue primarily through the manufacturing and sale of injectable pharmaceutical products. The company serves a diverse clientele, including hospitals, clinics, and pharmaceutical companies around the world. A significant portion of its income is derived from export sales to highly regulated markets like the United States, Europe, Canada, and Australia, where it supplies both generic injectables and contract manufacturing services. Additionally, the company partners with other pharmaceutical companies for co-development and out-licensing agreements, further enhancing its revenue streams. Its earnings are bolstered by its focus on producing complex and high-value products, which allows it to maintain competitive pricing and secure long-term contracts.

Gland Pharma Ltd. Financial Statement Overview

Summary

Gland Pharma Ltd. shows strong financial health with consistent revenue growth, solid profitability metrics, and a robust balance sheet. While there are concerns regarding recent declines in net income and free cash flow growth, overall financial management remains efficient.

Income Statement

Gland Pharma Ltd. has shown consistent revenue growth over the years, although there was a slight dip in 2025. The company maintains strong gross and net profit margins, with EBIT and EBITDA margins indicating efficient operational management. However, the recent decline in net income may point to potential challenges in maintaining profit margins.

Balance Sheet

The company demonstrates a robust balance sheet with a strong equity base and a low debt-to-equity ratio, indicating low financial leverage and risk. The equity ratio is solid, reflecting financial stability and a healthy capital structure. However, the slight increase in total liabilities over the years requires monitoring.

Cash Flow

Operating cash flow remains strong, supporting the company's ability to fund operations. The free cash flow is positive, though it has shown some fluctuations. The cash flow ratios suggest efficient cash management, yet the decrease in free cash flow growth rate in recent years could indicate challenges in cash generation.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2022	Dec 2022	Dec 2021
Income Statement
Total Revenue	56.17B	56.17B	56.42B	43.84B	36.25B	34.24B
Gross Profit	25.11B	33.27B	30.88B	22.75B	19.39B	19.32B
EBITDA	14.37B	12.69B	15.03B	17.34B	12.09B	14.37B
Net Income	6.99B	6.99B	7.72B	12.12B	7.81B	9.97B
Balance Sheet
Total Assets	112.25B	112.25B	106.61B	78.34B	87.78B	64.96B
Cash, Cash Equivalents and Short-Term Investments	30.50B	30.50B	19.39B	32.43B	38.36B	24.47B
Total Debt	3.14B	3.14B	3.72B	47.43M	44.53M	49.95M
Total Liabilities	20.74B	20.74B	19.37B	6.76B	8.19B	5.93B
Stockholders Equity	91.51B	91.51B	87.24B	71.58B	79.59B	59.03B
Cash Flow
Free Cash Flow	0.00	5.30B	5.99B	2.69B	1.41B	3.76B
Operating Cash Flow	0.00	9.15B	9.97B	7.91B	3.64B	6.05B
Investing Cash Flow	0.00	17.05B	-17.57B	-10.03B	12.08B	-15.24B
Financing Cash Flow	0.00	-4.33B	-7.99B	348.98M	149.19M	12.38B

Gland Pharma Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2020.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLAND, the sentiment is Positive. The current price of 2020.85 is above the 20-day moving average (MA) of 1921.57, above the 50-day MA of 1932.98, and above the 200-day MA of 1682.45, indicating a bullish trend. The MACD of 5.33 indicates Negative momentum. The RSI at 65.59 is Neutral, neither overbought nor oversold. The STOCH value of 77.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:GLAND.

Gland Pharma Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DRREDDY	76 Outperform	₹1.10T	19.33		0.61%	15.86%	2.02%
AUROPHARMA	76 Outperform	₹635.75B	18.75		0.37%	7.76%	-2.84%
SUNPHARMA	73 Outperform	₹3.88T	37.39		0.99%	9.28%	-0.17%
TORNTPHARM	73 Outperform	₹1.21T	60.29		0.90%	7.63%	15.39%
GLAND	69 Neutral	₹332.95B	43.23		0.89%	-2.34%	6.64%
GLAXO	66 Neutral	₹470.09B	49.47		1.94%	6.65%	48.47%
Sector *	51 Neutral	$7.93B	-0.35	-43.30%	2.25%	22.54%	-2.22%

Gland Pharma Ltd. Corporate Events

Gland Pharma Appoints New Secretarial Auditors to Strengthen Governance

Gland Pharma Limited has announced the appointment of M/s. RVR & Associates as the Secretarial Auditors for a term of five years, following approval at the company’s 47th Annual General Meeting. This strategic appointment is expected to enhance the company’s compliance management and corporate governance, potentially strengthening its market position and stakeholder confidence.